How Risky Is Amgen's At-Risk Launch Of Herceptin, Avastin Biosimilars?
Executive Summary
In ongoing patent litigation with Genentech, Amgen may need to reveal its counsel's advice on whether it should launch, while Genentech must produce its settlement agreements with Mylan, Celltrion, and Pfizer.
You may also be interested in...
COVID-19 Impacting Patent Litigation, From Exclusivity Forfeiture To Launch Delays
Pandemic poses new hurdles for Hatch-Waxman and BPCIA litigants as they navigate US FDA approval times, sponsor filing deadlines and biosimilar launch dates.
Amgen And Allergan Report ‘Positive’ Results On Rituximab
Amgen and Allergan have announced positive top-line results from a pivotal clinical study of their rituximab biosimilar version of Roche’s blockbuster biologic Rituxan to treat patients with non-Hodgkin's lymphoma.
For US Trastuzumab Biosimilars, Development Time Did Not Predict Speed To Market
Amgen/Allergan's Kanjinti had second longest development time among five licensed biosimilars to Genentech's Herceptin but was the first to reach market, according to a Pink Sheet timeline of development and regulatory milestones for the follow-on products.